FDA Compliance for Peptide Therapy and BPC 157 Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law Gray Market Peptides: So Much Hype, So Little Data RFK Jr. and the Perils of Peptides Washington Monthly An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica